1. Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.
- Author
-
Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Seiji Arihiro, Hiroo Imazu, Hiroshi arakawa, Shin Kan, Hideo Komita, Yuko Kamata, Masaki Ito, Toshifumi Ohkusa, Gong, Jianlin, and Hisao Tajiri
- Subjects
- *
ANTINEOPLASTIC agents , *DENDRITIC cells , *CELL fusion , *TUMOR antigens , *CYTOTOXIC T cells , *MESSENGER RNA - Abstract
The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumor-associated antigens (TAAs). although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumor-specific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF